Form 4: Bayer Healthcare Converts Preferred Stock to Common Stock in Senti Biosciences

Bayer Healthcare LLC converted its Series A Convertible Preferred Stock into 2,222,000 shares of Senti Biosciences common stock following stockholder approval.

Summary

• Bayer Healthcare LLC converted 2,222 shares of Series A Convertible Preferred Stock into 2,222,000 shares of Senti Biosciences, Inc. common stock on March 10, 2025.
• The conversion was triggered by the announcement of stockholder approval of the issuance of common stock upon conversion of the Series A shares, which occurred on March 7, 2025.
• Bayer Healthcare LLC directly holds 2,809,848 shares of common stock after the reported transaction.
• Bayer Healthcare LLC also holds warrants to purchase 3,330,000 shares of common stock with an exercise price of $2.3, expiring on December 9, 2029.
• The reporting entities include Bayer Healthcare LLC, Bayer US Holding LP, Bayer World Investments B.V., and Bayer Aktiengesellschaft, reflecting their indirect control and beneficial ownership.

Sentiment

Score: 7

Explanation: The document reflects a planned conversion of preferred stock to common stock, indicating a positive step in the company's capital structure. Bayer's continued investment is also a positive sign.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Senti Biosciences.
• Bayer's continued holding of common stock and warrants indicates ongoing investment in Senti Biosciences.

Risks

• The document does not explicitly mention any risks.
• However, large conversions of preferred stock to common stock can sometimes create short-term price volatility.

Future Outlook

The document does not contain explicit forward-looking statements, but Bayer's continued investment suggests a positive outlook on Senti Biosciences.

Industry Context

This conversion is a corporate action related to Senti Biosciences' capital structure and Bayer's investment in the company, reflecting ongoing activity in the biotechnology sector.

Comparison to Industry Standards

• Similar conversions of preferred stock to common stock are common in the biotechnology industry, especially after key milestones are achieved.
• Bayer's investment and stock holdings are comparable to other strategic investments by large pharmaceutical companies in smaller biotech firms.

Stakeholder Impact

• The conversion of preferred stock to common stock may impact shareholders by increasing the number of outstanding shares.
• The conversion simplifies the capital structure, which could be viewed positively by investors.

Key Dates